Remove 2001 Remove Clinical Trials Remove Data Remove Treatment
article thumbnail

Pushing Cannabis into Modern Healthcare

CannaTech

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions. Changing Cannabis Conversations Worldwide.

article thumbnail

Best strains and terpenes for migraine relief

The Cannigma

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month.

Terpenes 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mixing weed and alcohol: the good, the bad and the ugly

The Cannigma

A clinical trial published in 2015 found that the test subjects had “significantly higher blood THC” levels when they used cannabis along with alcohol, and combining the two led to increased performance impairment. The researchers added that people in treatment for AUD might benefit from stopping or reducing their cannabis use.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

At the same time, the outlook on cannabis research data is largely positive. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). The latter remains a dangerous drug and is considered higher risk for treatment than CBD (TGA 2019 ). Data collection.

article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

there has never been a better time for new treatment options. Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/rosalind-watts-89527660/.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015. Fabricio A.